# Sempresto

The Always There autoinjector, on your phone

- Canonical URL: https://wefunder.com/sempresto
- Entity ID: wefunder:company:195252
- Last updated: 2026-08-26T05:04:53Z
- Generated at: 2026-08-26T05:26:19Z

## Quick facts
- Backed by $2.6M angel investment and Jefferson University Partnership
- FDA filing targeted within 18 months, with no clinical trials required
- Medtech leadership team trained at Harvard, MIT, Wharton, Johns Hopkins & UPenn Medicine
- 15 patents granted, 10 pending across phone-based autoinjector technology (US & ex-US)
- Targeting a $3B+ addressable market; 33M Americans living with food allergies
- World-class team with 3 IPOs and 30+ commercial product launches
- 85%+ projected gross margins at scale, priced below the current market average (not guaranteed)
- Innovative autoinjector designed to attach to a smartphone, compatible with 95% of phones

## Active fundraises
- wefunder:fundraise:160645: 4(a)(6) successful (USD)
- wefunder:fundraise:160644: 4(a)(6) open (USD)

## Story
Sempresto is building the future of emergency rescue medication delivery, designed for how patients actually live.Today, 33 million Americans live with life-threatening allergies and most carry epinephrine for life. Yet fewer than 40% actually have their epinephrine with them when they need it most. Even fewer use it properly before reaching the emergency room. Most reported deaths and poor outcomes from anaphylaxis are linked to delayed administration. The drug is highly effective, but the device is failing the patient.Our lead product is Epinephrine, an FDA-approved, life-saving anaphylaxis treatment first introduced in 1901. The epinephrine autoinjector has not meaningfully evolved since it came to market in 1987. Sempresto’s first-of-its-kind, cellphone-integrated autoinjector is bringing emergency medicine delivery into the modern era.Our physician-invented autoinjector attaches directly to a cellphone, making life-saving medications effortless to carry and hard to leave behind.Invented by the Chief Physician Executive at Jefferson Health (one of the largest academic health systems in the country) and protected by 15 issued patents and 10 pending patent applications, Sempresto pairs trusted autoinjector technology with a companion app connected to 24/7 emergency room tele-health, creating an anaphylaxis solution built for how patients actually live.With a product launch targeted for 2028, and a platform engineered for expansion into other rescue medications, Sempresto is tackling a $3B+ US addressable market and a ~$6B+ global opportunity. Collectively our team has led 3 IPOs, filed 12 SEC Form S-1s, completed 30+ business development transactions, and holds 36 issued US patents.For the first time, everyday investors can own a stake in changing the way life-saving medications are delivered to patients all over the world. Join us in saving lives with Sempresto.Every year in the United States, people die from anaphylaxis who don’t have to.Epinephrine is widely prescribed, proven, and effective. The single biggest barrier to prompt treatment is a failure to carry.And the scale is staggering. 33 million Americans live with food allergies and fewer than 40% of patients have epinephrine accessible when an emergency strikes.The problem is most acute for teens and young adults - the highest-risk groups for fatal anaphylaxis, and the least likely to carry their device. A bulky autoinjector doesn't fit in a small bag, on the playing field, or on a night out. The data confirms what patients already know.Current innovation in this space addresses how the device is used, not whether patients actually have it with them. The FDA itself has identified failure-to-carry as the primary unmet need in anaphylaxis response. Sempresto is filling that gap.Picture this: a teenager heads to prom, a Sempresto autoinjector on the back of their phone, no need for a parent to nervously text "Did you remember it?" A runner hits the trail alone at 6am. A kid with a peanut allergy tears into a birthday cake. A college student loses themselves in a concert. In every one of these moments, the medication is there because the phone is there.Sempresto is developing an end-to-end emergency medicine delivery platform built by, and for, patients. A companion app will provide guidance and refill reminders so patients never run out, never carry expired medication, and always know how to use it.When an emergency happens, the app will be designed to connect patients to an emergency medicine professional in seconds through our partner platform, Health Alliance Global’s Dr. Triage. GPS integration will direct EMTs to the patient's exact location when further care is needed.The Sempresto autoinjector attaches directly to any MagSafe/Qi2 compatible cellphone. It is slim enough to slide into a pocket, ergonomically designed to fit comfortably in the palm of a hand, and simple to use in seconds.Our 15 issued patents and 10 pending applications cover device design, integration, safety mechanisms, heat shielding, and connectivity. Our patent portfolio offers broad coverage for the attachment of an autoinjector to a mobile device, both domestically and internationally.Medicine is moving to where patients already are. The Apple Watch now tracks blood pressure, respiratory rate, and blood oxygen concentration. Platforms like Hims/Hers and GoodRx have transformed how millions of people access and manage their healthcare. The future of medicine is digital, mobile, and patient-driven, and Sempresto is positioned squarely at the center of this future.In an independent study of 300 allergy patients and parents across the United States, the response to Sempresto was unambiguous. 92% said that they would purchase a Sempresto autoinjector instead of or in addition to their current autoinjector.The medical and scientific community has taken notice. In December 2025, Thomas Jefferson University announced a broad, strategic partnership with Sempresto, expanding on an exclusive license for the core platform technology invented by Sempresto Co-Founder, Dr. Edmund Pribitkin.As the Chief Physician Executive and EVP at Jefferson Health and chair of Sempresto's Scientific Advisory Board, Dr. Pribitkin brings both the clinical authority and personal conviction behind this mission.With nearly $3M committed from lead investors, patient demand validated by independent research, and the backing of one of the country's leading academic medical institutions, Sempresto has the foundation to bring this technology to the patients who need it most.Sempresto was built by people who understand this problem from both sides. Several of us carry epinephrine ourselves, are parents of children with severe allergies, or have responded to anaphylaxis emergencies firsthand. Our commitment to getting this product to market runs deeper than a business opportunity.But personal stakes alone don't bring a medical device to market. The team offers something rare: a clinician-inventor with deep institutional backing, seasoned medtech operators who have taken companies from lab to launch, and business builders with a track record of raising hundreds of millions and delivering exits.We know the FDA clearance process from the inside, having navigated regulatory pathways across pharma, medical devices, and biotech throughout our careers. Collectively we have led 3 IPOs, filed 12 SEC Form S-1s, completed 30+ business development transactions, and hold 36 issued US patents.Our executive team was trained at Harvard College, Harvard Medical School, MIT, Wharton, Johns Hopkins, and UPenn Medicine, and have spent their careers doing exactly what Sempresto now requires: building, funding, and commercializing life science and medical device companies.Sempresto's immediate addressable market is the 33 million Americans living with food allergies and the millions more affected by bee sting or medication allergies. The broader epinephrine autoinjector market is valued at $3B+ in the United States and is estimated at $6B+ globally.Food allergies are on the rise, with ER visits for food-induced anaphylaxis in children increasing year over year. And unlike most medical conditions, anaphylaxis requires a lifelong prescription: once diagnosed, whether from food, bee stings, or medication, patients are expected to carry epinephrine with them everywhere, every day, for the rest of their lives.But epinephrine is just the beginning. The same carry problem affects millions of people who rely on other emergency injectable medications every day.Each of these conditions represents a patient population that needs to carry medication with them at all times and struggles with the same fundamental problem Sempresto is built to solve. Sempresto's IP position covers the integration of autoinjectors and other delivery mechanisms with mobile devices broadly, not just epinephrine.We anticipate generating revenue through two complementary streams: device sales and subscription revenue sharing with our tele-health partners.Sempresto will be a prescription product sold through standard pharmaceutical channels. At launch, product cost is projected to be < $40 fully landed, with a retail sales price targeted below the estimated market average of $225 per unit, making Sempresto immediately competitive on price.As volume scales, unit costs are projected to drop by almost 60% to well under $20, with gross margins above 85% anticipated at launch and even higher at scale. Patients also refill autoinjector prescriptions on an annual basis, creating a predictable, repeating revenue stream.The companion app will include a free tier, providing training, guidance, and refill reminders for all patients. An optional premium subscription tier will unlock 24/7 tele-health access to emergency medicine practitioners. Sempresto will split subscription revenue with its tele-health partner, Health Alliance Global, whose infrastructure is already built and licensed across 40+ states, meaning Sempresto will carry no additional infrastructure cost.The result is a model built for cumulative lifetime value: patients refill and subscribe, and as the platform expands into new rescue medications over time, the revenue opportunity grows along with it.Future projections are not guaranteed.Sempresto is on a path to filing for FDA and EMEA clearance and a planned commercial launch in 2028. Our financial roadmap reflects a staged ramp approach. We’ll target the US and EU for initial epinephrine sales, with expansion into tele-health subscription revenue, seizure device sales, nasal spray device and other rescue medication sales in subsequent years.Future projections are not guaranteed.Since its founding in 2024, Sempresto has moved fast. We have developed working prototypes, built and amassed a portfolio of two dozen issued and pending patents, secured millions in funding, and announced a key strategic partnership, all within our first two years.Most epinephrine innovations take nearly a decade to reach patients. Sempresto is targeting US and EU commercial launch in 2028, less than three years from today.The reason comes down to regulatory strategy. While competitors develop new drugs or novel formulations requiring full clinical trial programs, Sempresto will be delivering an existing, FDA-cleared medicine through a new device.The 505(b)(2) pathway allows Sempresto to leverage decades of existing safety and efficacy data on epinephrine, requiring only demonstration that the device delivers the dose correctly and that patients can use it properly. It’s a regulatory strategy that most companies in this space are not positioned to use, and it puts Sempresto years ahead of a traditional drug development timeline.The epinephrine autoinjector space has a well-documented history of acquisitions. Companies with validated IP and a credible path to market have repeatedly attracted strategic buyers, at every stage of development, not just at commercial scale.Sempresto sees three credible exit pathways. The first is an early acquisition upon FDA filing, when a strategic buyer acquires the IP and program, to take advantage of regulatory momentum before full commercialization. The second is a post-launch acquisition, once revenue and market share data are established, commanding a higher valuation. The third is an IPO, a longer-term path should Sempresto choose to build out its full commercial infrastructure independently.The comparable exits speak for themselves.Future projections are not guaranteed. There is no guarantee of an exit opportunity.Investors will receive perks at their level of investment in addition to the perks of the levels under that amount.Every year, too many people die from anaphylaxis. They filled their prescription for a medication that could have saved them but they did not have it when they needed it. That is not a medical failure. It is a design failure. Sempresto is here to fix it.Sempresto is for the millions of Americans living with life-threatening allergies. For the parents who text their child before every school event to make sure they remembered it. For the teenagers who leave it at home because it doesn't fit in their life. For the caregivers, the coaches, the school nurses who carry the weight of someone else's emergency.Sempresto has the science, the IP, the regulatory pathway, and a team that has built and exited companies before. What we need now is the community behind us.For the first time, everyday investors can own a stake in a medical device being built by and for the people who need it most. Invest today.

## Team
- Elizabeth Reczek (Co-Founder & CEO)
- Edmund Pribitkin (Co-Founder & SAB Chairman)
- Shawn Marcell (Co-Founder & Executive Chairman)
- Greg Dale (CTO)
- Scott Hollander (COO)
- Matthew Copeland (CFO)

## Recent posts
- We built the autoinjector designed for how patients actually live (2026-08-25T17:36:04Z)